Adverum Biotechnologies, Inc.
ADVM · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $106 | $45 | $91 | $98 |
| - Cash | $26 | $42 | $49 | $61 |
| + Debt | $89 | $92 | $93 | $92 |
| Enterprise Value | $169 | $95 | $136 | $129 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$47 | -$49 | -$48 | -$61 |
| % Margin | – | – | – | – |
| Net Income | -$48 | -$49 | -$47 | -$61 |
| % Margin | – | – | – | – |
| EPS Diluted | -2.03 | -2.34 | -2.25 | -1.96 |
| % Growth | 13.2% | -4% | -14.8% | – |
| Operating Cash Flow | -$28 | -$39 | -$43 | -$28 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$28 | -$39 | -$43 | -$28 |